Tower Research Capital LLC (Trc) Nurix Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 14,885 shares of NRIX stock, worth $223,275. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,885
Previous 2,849
422.46%
Holding current value
$223,275
Previous $63,000
344.44%
% of portfolio
0.01%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
70.6MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$102 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$65.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$62.9 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$58.2 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$53.8 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $707M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...